NEW ORLEANS, LOUISIANA / ACCESS Newswire / November 12, 2025 / American Heart Association (“AHA”) Conference 2025, GENinCode ...
More than 70% of people over 70 years old will one day develop cardiovascular disease, highlighting the need for effective ...
Cardiovascular diseases (CVDs) are the leading cause of non-communicable disease (NCD) deaths in India, accounting for nearly ...
Researchers sought to compare an AI model vs multiple existing risk scores for their ability to predict positive CAC among middle-aged adults.
News-Medical.Net on MSN
New data supports earlier use of evolocumab in high-risk diabetes
Adding the PCSK9 inhibitor evolocumab to a high-intensity, cholesterol-lowering regimen reduced the risk of a first major ...
In patients with atherosclerosis and/or diabetes without a prior heart attack or stroke, evolocumab cut the risk for first ...
MedPage Today on MSN
Evolocumab Reduced First CV Events in Patients Without Prior MI or Stroke
NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac ...
An oral agent is needed because some patients don’t like injectables, and some doctors don’t prescribe them, experts say.
Navar A. Efficacy and safety of enlicitide, an oral PCSK9 inhibitor, for lowering LDL cholesterol in adults with or at-risk for ASCVD: the phase 3 CORALreef lipids trial. Presented at: AHA 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback